LBT Innovations Ltd is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange in July 2006 (ASX: LBT). 

The company’s ambition is to become a leader in innovation in the international pathology laboratory market with multiple products to take to that market. 

LBT Innovations receives milestone and royalty payments for its first product, marketed globally as PREVI™ Isola, which automates the inoculation and streaking of culture plates in clinical microbiology laboratories.

The company is actively pursuing growth of its technology pipeline and is currently evaluating commercialisation options for its second product, APAS, which automates the screening and interpretation of agar plates following incubation.